Skip to main content
. 2019 Apr;10(2):226–234. doi: 10.21037/jgo.2018.12.10

Figure 1.

Figure 1

Survival curve of 2-year overall survival (OS) in patients with colon cancer treated with oxaliplatin-containing adjuvant chemotherapy based on ECOG performance status. Patients with ECOG 1 and ECOG 2 performance status had 2-year OS of 82.9% and 66.4% (HR =2.967; 95% CI, 1.265–6.957; P=0.012). ECOG, the Eastern Cooperative Oncology Group.